Sunday 18 October 2026
Export HUMA’s income statement to Excel — free account
Humacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022. In the quarter to June 2026, revenue grew 34.9%, EPS grew 33.3%, free cash flow grew 17.9% and total debt rose 437.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.43
0.01
−2.27%
Follow HUMA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 9.65 | 7.08 | 1.96 | 1.96 | 2.48 | 0.91 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 10.33 | 17.45 | 8.04 | 5.60 | 9.97 | 5.48 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 2 | 2 | 146 | 164 | 185 | 220 | 184 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.75 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | 1 | 2 | — | — | 2 | ||||
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | — | — | (376.05) | |||||
| EBT | — | — | — | — | (67) | (26) | (12) | (111) | (149) | (41) | |||||
| EBT margin, % | — | — | — | — | (4,461.70) | (2,096.36) | (764.54) | 0.00 | 0.00 | (2,003.58) | |||||
| Net income | — | 0 | — | 0 | (67) | (26) | (12) | (111) | (149) | (41) | |||||
| Depreciation | — | — | — | — | 8 | 9 | 10 | 8 | 7 | 7 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.26 | 0.03 | 0.02 | 0.00 | 0.00 | 0.01 | ||||
| Earnings | — | — | — | — | (11.54) | (0.66) | (0.12) | (1.07) | (1.26) | (0.26) | |||||
| Cash flow | — | — | — | — | (9.64) | (2.03) | (0.69) | (0.71) | (0.83) | (0.66) | |||||
| Capex | — | — | — | — | (0.05) | (0.01) | (0.01) | (0.02) | (0.01) | (0.01) | |||||
| Free cash flow | — | — | — | — | (9.68) | (2.04) | (0.70) | (0.73) | (0.84) | (0.67) | |||||
| Book value | — | — | — | — | (60.76) | 3.06 | 1.13 | 0.13 | (0.44) | 0.02 | |||||
| Shares, m | — | — | — | — | 6 | 40 | 103 | 103 | 118 | 158 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 229.44 | 138.94 | — | — | 74.50 | |||||
| P/B | — | — | — | — | 1.13 | 2.37 | 1.86 | — | — | 48.84 | |||||
| EV/Sales | — | — | — | — | 0.00 | 89.28 | 66.94 | — | — | 80.36 | |||||
| EV/FCF | — | — | — | — | 0.00 | (1.39) | (1.45) | — | — | (1.55) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (56) | (81) | (71) | (73) | (98) | (105) | ||||
| Capex | — | — | — | — | 0 | 0 | (1) | (2) | (2) | (1) | |||||
| Free cash flow | — | — | — | — | (56) | (81) | (72) | (76) | (100) | (106) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 30 | 218 | 135 | 65 | 28 | 49 | ||||
| Total debt | — | — | — | — | 23 | 48 | 39 | 16 | 14 | 62 | |||||
| Net debt | — | — | — | — | (17) | (177) | (113) | (64) | (31) | 12 | |||||
| Shareholders’ equity | — | — | — | — | (350) | 122 | 117 | 14 | (53) | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (124.71) | (13.47) | (4.88) | (66.63) | (111.77) | (32.12) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (1,247.32) | 0.00 | 0.00 | (449.67) | |||||
| ROE | — | — | — | — | 58.32 | 23.21 | (10.01) | (169.81) | 760.17 | 164.78 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Humacyte, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics, Inc. | $126.9M | — (loss-making) | — (loss-making) | −39.13% (below 0%: shrinking) | n/m | +24.80% (above 0%: growing) | 100.00% | (833.87%) | Compare |
| HUMA Humacyte, Inc. | $122.1M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | |
| OTLK Outlook Therapeutics, Inc. | $121.7M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRB Spruce Biosciences, Inc. | $119.2M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $117.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| HURA TuHURA Biosciences, Inc. | $116.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| Median of peers | $118.3M | — | — | −57.50% | — | −73.50% | 19.35% | (205.42%) |
Humacyte, Inc. (HUMA) key facts
- Strength: Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022.
- Humacyte, Inc. (HUMA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, HUMA traded at $0.43, a market capitalization of $122.1 million.
- Return on equity was 164.8% and debt-to-equity 2.07.
- Its Altman Z-score is −10.48 (distress zone) for fiscal 2025.